Inovio Biomedical's DNA Delivery Technology Significantly Enhances Potency of Gene-Based Prostate Cancer Vaccine
Key Milestone for First-in-Man DNA Vaccine Clinical Trial Using Inovio's Electroporation DNA Delivery Technology
Inovio Biomedical Corp., focused on the development of DNA-based vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced that interim data from a clinical study of an experimental DNA-based prostate cancer vaccine demonstrated that Inovio's DNA delivery technology significantly enhanced the potency of the gene-based vaccine.
The results demonstrated safety, tolerability and significantly higher antibody responses for patients who received the vaccine with Inovios delivery system versus those who were treated without it. Inovios electroporation-mediated DNA delivery system is designed to enhance the potency of DNA-based immunotherapies against cancers and infectious diseases.
An analysis of interim data from the first and partially from the second dose treatment groups demonstrated the following points:
1. Electroporation appears safe and it is well tolerated.
2. The number of patients with significant antibody responses was four of 10 in the patient groups treated without electroporation compared to nine of 10 in the patient groups treated with electroporation.
3. The magnitude of the antibody response was significantly higher in patients treated using electroporation. Data on the T-cell response is being compiled.
The investigators continue to enroll and treat patients in the higher-dosage treatment groups.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Personalized cancer therapy with a "mini-tumour" and digital twin

Clipster® Blades for Tool Size L | Sterile disconnectors | Sartorius

Patenting by European universities on the rise - High concentrations of academic patents at some universities and in some countries

Intralabs - Bengaluru, India
PharmaStem Patents Confirmed after Reexamination by Patent Office
ICo Therapeutics Signs Collaboration Agreement with The Consortium for Parasitic Drug Development
VITA 34: Positive Results in Q2 2009
